Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Tulika Ranjan; Soma Sengupta; Michael J. Glantz; Richard M. Green; Alexander Yu; Dawit Aregawi; Rekha Chaudhary; Ricky Chen; Mario Zuccarello; Christine Lu-Emerson; Hugh D. Moulding; Neil Belman; Jon Glass; Aaron Mammoser; Mark Anderson; Jagan Valluri; Nicholas Marko; Jason Schroeder; Steven Jubelirer; Frances Chow; Pier Paolo Claudio; Anthony M. Alberico; Seth T. Lirette; Krista L. Denning; Candace M. Howard

doi:10.1016/j.xcrm.2023.101025

Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Tulika Ranjan, Soma Sengupta, Michael J. Glantz, Richard M. Green, Alexander Yu, Dawit Aregawi, Rekha Chaudhary, Ricky Chen, Mario Zuccarello, Christine Lu-Emerson, Hugh D. Moulding, Neil Belman, Jon Glass, Aaron Mammoser, Mark Anderson, Jagan Valluri, Nicholas Marko, Jason Schroeder, Steven Jubelirer, Frances ChowPier Paolo Claudio, Anthony M. Alberico, Seth T. Lirette, Krista L. Denning, Candace M. Howard

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2–14.7) compared with 9 months (95% CI, 4.2–13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24–0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.

Original language	English (US)
Article number	101025
Journal	Cell Reports Medicine
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/j.xcrm.2023.101025
State	Published - May 16 2023

All Science Journal Classification (ASJC) codes

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.xcrm.2023.101025

Cite this

Ranjan, T., Sengupta, S., Glantz, M. J., Green, R. M., Yu, A., Aregawi, D., Chaudhary, R., Chen, R., Zuccarello, M., Lu-Emerson, C., Moulding, H. D., Belman, N., Glass, J., Mammoser, A., Anderson, M., Valluri, J., Marko, N., Schroeder, J., Jubelirer, S., ... Howard, C. M. (2023). Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. Cell Reports Medicine, 4(5), Article 101025. https://doi.org/10.1016/j.xcrm.2023.101025

@article{ca202187b2514815b8424d5a55470298,

title = "Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial",

abstract = "Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2–14.7) compared with 9 months (95% CI, 4.2–13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24–0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.",

author = "Tulika Ranjan and Soma Sengupta and Glantz, {Michael J.} and Green, {Richard M.} and Alexander Yu and Dawit Aregawi and Rekha Chaudhary and Ricky Chen and Mario Zuccarello and Christine Lu-Emerson and Moulding, {Hugh D.} and Neil Belman and Jon Glass and Aaron Mammoser and Mark Anderson and Jagan Valluri and Nicholas Marko and Jason Schroeder and Steven Jubelirer and Frances Chow and Claudio, {Pier Paolo} and Alberico, {Anthony M.} and Lirette, {Seth T.} and Denning, {Krista L.} and Howard, {Candace M.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = may,

day = "16",

doi = "10.1016/j.xcrm.2023.101025",

language = "English (US)",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "5",

}

Ranjan, T, Sengupta, S, Glantz, MJ, Green, RM, Yu, A, Aregawi, D, Chaudhary, R, Chen, R, Zuccarello, M, Lu-Emerson, C, Moulding, HD, Belman, N, Glass, J, Mammoser, A, Anderson, M, Valluri, J, Marko, N, Schroeder, J, Jubelirer, S, Chow, F, Claudio, PP, Alberico, AM, Lirette, ST, Denning, KL & Howard, CM 2023, 'Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial', Cell Reports Medicine, vol. 4, no. 5, 101025. https://doi.org/10.1016/j.xcrm.2023.101025

TY - JOUR

T1 - Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

AU - Ranjan, Tulika

AU - Sengupta, Soma

AU - Glantz, Michael J.

AU - Green, Richard M.

AU - Yu, Alexander

AU - Aregawi, Dawit

AU - Chaudhary, Rekha

AU - Chen, Ricky

AU - Zuccarello, Mario

AU - Lu-Emerson, Christine

AU - Moulding, Hugh D.

AU - Belman, Neil

AU - Glass, Jon

AU - Mammoser, Aaron

AU - Anderson, Mark

AU - Valluri, Jagan

AU - Marko, Nicholas

AU - Schroeder, Jason

AU - Jubelirer, Steven

AU - Chow, Frances

AU - Claudio, Pier Paolo

AU - Alberico, Anthony M.

AU - Lirette, Seth T.

AU - Denning, Krista L.

AU - Howard, Candace M.

PY - 2023/5/16

Y1 - 2023/5/16

N2 - Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2–14.7) compared with 9 months (95% CI, 4.2–13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24–0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.

AB - Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2–14.7) compared with 9 months (95% CI, 4.2–13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24–0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.

UR - http://www.scopus.com/inward/record.url?scp=85159223994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159223994&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2023.101025

DO - 10.1016/j.xcrm.2023.101025

M3 - Article

C2 - 37137304

AN - SCOPUS:85159223994

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 5

M1 - 101025

ER -

Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this